192MO Primary endpoint of ROSALINE: A phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC)
Authors:
- S. Lobo-MartinsSLS. Lobo-Martins
- E. AgostinettoEAE. Agostinetto
- F.P. DuhouxFDF.P. Duhoux
- J.T.L. Ribeiro MouratoJMJ.T.L. Ribeiro Mourato
- P. NevenPNP. Neven
- C. Chakiba BrugereCBC. Chakiba Brugere
- J-L. CanonJCJ-L. Canon
- F. CoussyFCF. Coussy
- D. TaylorDTD. Taylor
- C. FontaineCFC. Fontaine
- H. DenysHDH. Denys
- M. Houinsou HansMHM. Houinsou Hans
Open Access